- Saudi Arabia
- Egypt
- Qatar
- United Arab Emirates
September 7, 2026
Share
Last updated: 7/9/2026
The term Rybelsus for weight loss has become increasingly common as semaglutide medicines have gained attention. However, the first step is to understand what Rybelsus is and what it was registered to treat. Rybelsus is a prescription medicine containing oral semaglutide. Weight loss may occur while taking it, but that does not make it suitable for everyone who wants to lose weight.
The right decision does not start with the question, “How many kilograms will I lose?” It starts with a more important question: “Is this medicine appropriate for my condition in the first place?” Any decision about Rybelsus for weight loss should begin with medical suitability, not a target number on the scale. This article explains the difference between approved use and the weight loss that may occur during treatment, along with the main results, side effects, and warnings you should know.
In Saudi Arabia, the Saudi Food and Drug Authority lists Rybelsus (semaglutide) as an anti-diabetic medicine and provides official risk-minimization information related to its administration and dosing. Its approved use is tied to diabetes care rather than general weight loss, and it should be used under medical supervision.
For this reason, Rybelsus for weight loss should not be treated as a general product for losing weight or selected based on another person’s experience. Registration status and approved indications may differ between markets, so the local product information and the treating physician remain the reference.
This distinction matters because the existence of other semaglutide products that are specifically intended for weight management does not mean that all semaglutide products are identical. This is particularly important when Rybelsus for weight loss is being considered. The brand name, formulation, dose, and approved indication all need to be distinguished.
Semaglutide is a GLP-1 receptor agonist. It helps regulate blood glucose in people with type 2 diabetes, while also affecting appetite, fullness, and gastric emptying. As a result, some patients may eat less without experiencing the same level of hunger they had before treatment.
This is why Rybelsus for weight loss may be associated with a decrease in body weight in some users. However, it is not a medicine that directly “burns fat,” and it does not replace balanced nutrition, physical activity, sleep, and the other factors that influence body weight.
Hamad Medical Corporation’s National Obesity Treatment Center explains that obesity treatment is based on a comprehensive assessment and a personalized plan that may include medical weight management alongside healthier eating and physical activity.
There is no fixed result that applies to everyone. According to the updated U.S. prescribing information for Rybelsus, one trial in people with type 2 diabetes showed an average weight reduction after 26 weeks of about 2.3 kg with 7 mg and about 3.7 kg with 14 mg, compared with about 1.4 kg with placebo. In another trial, the average reduction was about 4.4 kg with 14 mg over 26 weeks.
These numbers are averages from study groups, not a promise that someone using Rybelsus for weight loss will lose the same number of kilograms. The studies cited above were conducted primarily in people with type 2 diabetes, so their results should not be directly applied to every person without diabetes.
Weight change usually does not happen within a few days. Appetite may change before a clear difference appears on the scale, and body weight may then change gradually over weeks and months. This is why Rybelsus for weight loss should be assessed over time rather than judged by a few days on the scale. The result depends on starting weight, food intake, activity, other medicines, and the body’s response to treatment.
More than one medicine may contain the same active ingredient, but that does not make the products automatically interchangeable. Rybelsus has primarily been associated with the treatment of type 2 diabetes, while other semaglutide products are specifically intended for weight management under defined medical criteria.
Importantly, the OASIS 4 study evaluated oral semaglutide 25 mg in adults with overweight or obesity without diabetes and reported a mean weight reduction of 13.6% at week 64, compared with 2.2% with placebo. This result relates to the dose and formulation studied for weight management and should not be presented as the expected result from standard Rybelsus.
In simpler terms, having the same active ingredient does not mean that product doses or treatment goals are equivalent. When evaluating Rybelsus for weight loss, results from another medicine or another dose should not be transferred directly to it. Calling Rybelsus a “diabetes medicine for weight loss” can oversimplify the issue and may encourage inappropriate use.
How Rybelsus tablets are taken matters because the absorption of oral semaglutide is affected by food, drinks, and other medicines. The tablet is taken in the morning on an empty stomach with a small amount of water, followed by a wait of at least 30 minutes before eating, drinking, or taking another oral medicine. The tablet should be swallowed whole and should not be crushed or chewed.
The NHS formulary guidance also notes that newer Rybelsus formulations with higher bioavailability come in different strengths from the older formulation, creating a risk of medication errors if old and new strengths are compared number for number.
For this reason, we do not recommend choosing or changing a dose of Rybelsus for weight loss on your own. The dose is determined according to the product available, the medical condition, and the physician’s treatment plan, not according to the number of kilograms a person wants to lose.
Cleveland Clinic explains that gastrointestinal side effects are among the most common effects people may notice with semaglutide tablets. They may be more noticeable when treatment is started or during dose adjustments.
Before using Rybelsus for weight loss, it is useful to know that digestive symptoms are relatively common and can vary in severity. A mild symptom does not automatically mean that the medicine must be stopped, but persistent vomiting, diarrhea, or difficulty eating and drinking should be discussed with a doctor. Dehydration can increase the risk of kidney problems in some patients.
One of the most important points to know when using Rybelsus for weight loss is that some symptoms need prompt evaluation. Seek medical assessment if you develop severe and persistent abdominal pain, especially if it spreads to the back, because this may be a sign of pancreatitis. Persistent vomiting or diarrhea with dehydration, severe allergic symptoms, or upper abdominal pain with yellowing of the skin or eyes also require medical attention.
The risk of low blood sugar may increase when Rybelsus is used with insulin or certain medicines that stimulate insulin release. Patients should therefore know the signs of hypoglycemia and follow the management plan provided by their clinician.
Rybelsus is also not recommended in severe gastroparesis. If you have known problems involving the stomach, pancreas, gallbladder, or kidneys, tell your doctor before starting treatment. These conditions should be reviewed before Rybelsus for weight loss is considered.
Yes, but more than one issue needs to be distinguished. If a patient uses Rybelsus for weight loss or for diabetes and already has diabetic retinopathy, a rapid improvement in blood glucose may be associated with temporary worsening of retinopathy in some patients. This is why appropriate eye follow-up is important.
In 2025, the European Medicines Agency concluded that non-arteritic anterior ischemic optic neuropathy (NAION) is a very rare side effect of semaglutide and may affect up to 1 in 10,000 users. If sudden vision loss or rapid deterioration in vision occurs, medical assessment should not be delayed.
For more information about eye monitoring in people with diabetes, read Magrabi Health’s article on the effect of diabetes on the retina.
Rybelsus is not suitable for everyone. According to drug safety information, it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and in anyone with a previous serious hypersensitivity reaction to semaglutide or one of the medicine’s ingredients.
The doctor also needs to know about kidney, gallbladder, or pancreatic disease, severe stomach problems, diabetic retinopathy, or the use of other glucose-lowering medicines. For this reason, Rybelsus cannot be described as the best weight loss pills for everyone. A treatment that is suitable for one person may be inappropriate for another.
Rybelsus is not used for the purpose of losing weight during pregnancy, so Rybelsus for weight loss should not be started during this period. Product information also recommends stopping semaglutide sufficiently in advance of a planned pregnancy; the U.S. prescribing information specifies at least two months because the medicine remains in the body for a prolonged period.
During breastfeeding, treatment should be discussed with a doctor rather than decided independently. The choice depends on the reason for treatment, the mother’s condition, and the available alternatives, not on the goal of weight loss alone.
If you are taking Rybelsus for weight loss or for diabetes and are planning surgery, tell your doctor and anesthesia team. Semaglutide delays gastric emptying, which is relevant before surgery, endoscopy, or another procedure requiring general anesthesia or deep sedation. Rare reports have described aspiration of stomach contents during these procedures in people using GLP-1 medicines.
Do not stop Rybelsus for weight loss or diabetes treatment on your own before the procedure. The medical team decides whether treatment should be continued or temporarily withheld based on the procedure, your condition, and the risks of high blood glucose or retained stomach contents.
A person without diabetes should not start Rybelsus on their own simply to lose weight. Having overweight or obesity does not mean that every weight loss medication is suitable, because treatment selection depends on body mass index, associated conditions, current medicines, and the expected risks and benefits.
If you want to better understand obesity and when it may need medical evaluation, Magrabi Health provides additional patient education on obesity.
The term weight loss pills includes many products that differ widely in how they work and in their safety profiles. Rybelsus should not simply be placed on a list of weight loss drugs and selected according to other people’s experiences or the speed of weight loss they report.
The Egyptian Drug Authority emphasizes the rational use of diabetes medicines and the importance of selecting treatment for each patient under professional supervision, rather than relying on self-directed medicine use for weight loss. This supports the same principle: Rybelsus for weight loss should not be chosen through self-treatment.
There is no single answer that applies to everyone. When comparing Rybelsus for weight loss with other weight loss tablets, the first step is to understand the cause of excess weight, body mass index, whether diabetes or other conditions are present, current medicines, and whether medication is appropriate at all.
For this reason, Rybelsus for weight loss should not automatically be considered a better option, and treatment should not be selected simply because it reduces appetite. The goal is a safe treatment that fits the individual and can be medically monitored, not the fastest possible change on the scale.
Tell your doctor about every medicine and supplement you use, and about any history of problems involving the pancreas, gallbladder, kidneys, stomach, or eyes. It is also important to mention insulin or other diabetes medicines, pregnancy or plans for pregnancy, breastfeeding, and any upcoming surgery or procedure that will require anesthesia.
This information helps the doctor decide whether Rybelsus for weight loss or diabetes treatment is appropriate, what follow-up is needed, and how side effects or drug interactions can be reduced.
Rybelsus for weight loss may be associated with reduced body weight in some users, but Rybelsus remains a prescription medicine with specific indications, administration instructions, and safety warnings. Do not select a dose based on another person’s experience, and do not assume that results from other semaglutide products or studies automatically apply to Rybelsus itself.
At Magrabi Hospitals, we recommend consulting a doctor before using any medicine for weight loss and seeking prompt medical evaluation if severe persistent abdominal pain, significant dehydration, sudden vision changes, or unusual symptoms develop during treatment.
Medical review: Reviewed by the Magrabi editorial team with the support of specialized physicians.
Disclaimer: This article is for health education purposes only and is not a substitute for consultation with a qualified healthcare professional.
The Magrabi Health Editorial Team creates educational medical content designed to help readers better understand symptoms, diagnostic tests, treatment options, and preventive healthcare measures across a wide range of medical topics, drawing on trusted sources and specialized clinical expertise. Since 1955, Magrabi Health has built more than 70 years of experience in specialized healthcare through a regional network of over 40 facilities across 5 countries. Its commitment to quality and patient safety is reflected in numerous accreditations and recognitions, including the designation of several eye centers as Centers of Excellence in Ophthalmology by the Surgical Review Corporation (SRC). This content is intended for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment.
Weight loss can occur while taking Rybelsus, but in Saudi Arabia it is registered primarily for adults with type 2 diabetes. Rybelsus for weight loss should not be used without a prescription and medical evaluation.
Some injections may share the same active ingredient as Rybelsus, but products differ in dose, formulation, route of administration, and approved indication. One product should not be substituted for another based only on the active ingredient name.
Results vary from person to person. Appetite may change first, while weight changes can take weeks or months. A specific number of kilograms or a single rate of weight loss cannot be guaranteed for everyone.
It is taken in the morning on an empty stomach with a small amount of water, followed by a wait of at least 30 minutes before food, drink, or another oral medicine. Follow the local product information and your doctor’s instructions.
The most common effects include nausea, abdominal pain, diarrhea, vomiting, constipation, and reduced appetite. Less common but important risks include pancreatitis, dehydration, gallbladder problems, and some eye complications.
People without diabetes should not start Rybelsus on their own for weight loss. If someone has overweight or obesity, a doctor should determine whether medication is needed and which approved treatment is most appropriate.
